Guidelines On Diabetes, Pre-Diabetes, And Cardiovascular Diseases: Executive Summary.The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient, suffering from a specific condition, taking into account not only the impact on outcome, but also the risk benefit ratio of a particular diagnostic or therapeutic procedure. The ESC recommendations for guidelines production can be found on the ESC website†. In brief, the ESC appoints experts in the field to carry out a comprehensive and critical evaluation of the use of diagnostic and therapeutic procedures and to assess the risk–benefit ratio of the therapies recommended for management and/or prevention of a given condition. The strength of evidence for or against particular procedures or treatments is weighed according to predefined scales for grading recommendations and levels of evidence, as outlined below. Once the document has been finalized and approved by all the experts involved in the Task Force, it is submitted to outside specialists for review. If necessary, the document is revised once more to be finally approved by the Committee for Practice Guidelines and selected members of the Board of the ESC. The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups, or consensus panels. The chosen experts in these writing panels are asked to provide disclosure statements of all relationships they may have, which might be perceived as real or potential conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements

To Alfred Deakin

OBJECTIVE: We estimated the prevalence, incidence and risk factors of left ventricular hypertrophy (LVH) in a prospective cohort study of 26 489 participants. MATERIAL AND METHODS: The LVH was defined as Minnesota Code 310 on electrocardiogram (ECG). Everyone with this code at first visit was defined as a prevalence case and those who developed it between subsequent visits were incidence cases. The comparison cohort were all other participants in the Reykjavik Study stages I-V. RESULTS: A total of 297 men and 49 women were found to have LVH of 3.2% and 0.5%, respectively. The incidence was 25 per 1000 per year amongst men and six per 1000 per year amongst women. Prevalence in both genders increased with increasing age. Risk factors at the time of diagnosis were systolic blood pressure [odds ratio (OR) per mmHg 1.02; 95% confidence interval (CI): 1.01-1.03], age (OR per year 1.04; 95% CI: 1.02-1.05), silent myocardial infarction (MI) (OR 3.18; 95% CI: 1.39-7.27) and ST-T changes (OR 3.06; 95% CI: 2.14-4.38) amongst men and systolic blood pressure and age for women with similar odds ratio. Predictive factors for acquiring LVH were systolic blood pressure [incidence ratio (IR) 1.01; 95% CI: 1.01-1.02] and angina with ECG changes (IR 2.33; 95% CI: 1.08-5.02) amongst men and systolic blood pressure amongst women (IR 1.03; 95% CI: 1.01-1.04). The risk for coronary mortality was significantly increased amongst women with hypertrophy [hazard ratio (HR) 3.07; 95% CI: 1.5-6.31] and their total survival was poorer with increasing time from diagnosis of LVH (HR 2.17; 95% CI: 1.36-3.48). CONCLUSIONS: We conclude that the presence of LVH and its appearance is associated with age and increased blood pressure amongst both genders. Women with LVH have poorer survival than other women and they are at threefold risk of dying of ischaemic heart disease

The epidemiology of right bundle branch block and its association with cardiovascular morbidity - the Reykjavik Study

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldThis study is based on the Reykjavik Study, a long-term prospective cardiovascular survey, which included a representative population of 9135 men and 9627 women, 33-79 years old, who were invited to participate during the years 1967-91. Right bundle branch block (RBBB) was found in 126 men and 67 women. The prevalence increased with age, from 0% among men and women 30-39 years of age to 4.1% and 1.6% in men and women, respectively, who where 75-79 years old. The incidence increased with age. In men younger than 60 years RBBB had a significant relationship with hypertension (P < 0.05), elevated fasting blood glucose (P = 0.05), and increased heart size (P < 0.05). In men with RBBB regardless of age, an association was found with cardiomegaly (P < 0.05), ischaemic heart disease (P < 0.05), arrhythmias (P < 0.001) and bradycardia (P < 0.01). A higher mortality from heart disease (P < 0.01) was found in men with RBBB compared to the control population. This was not significant when risk factors of heart disease were taken into account by multivariate Cox analysis. There was a relationship (P < 0.05) between hypertension and RBBB in women younger than 60 years. RBBB in women younger than 60 years is often associated with hypertension and in men younger than 60 it is often associated with an underlying cardiovascular disease, hypertension, cardiomegaly and elevated blood glucose

The epidemiology of right bundle branch block and its association with cardiovascular morbidity - the Reykjavik Study

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldThis study is based on the Reykjavik Study, a long-term prospective cardiovascular survey, which included a representative population of 9135 men and 9627 women, 33-79 years old, who were invited to participate during the years 1967-91. Right bundle branch block (RBBB) was found in 126 men and 67 women. The prevalence increased with age, from 0% among men and women 30-39 years of age to 4.1% and 1.6% in men and women, respectively, who where 75-79 years old. The incidence increased with age. In men younger than 60 years RBBB had a significant relationship with hypertension (P < 0.05), elevated fasting blood glucose (P = 0.05), and increased heart size (P < 0.05). In men with RBBB regardless of age, an association was found with cardiomegaly (P < 0.05), ischaemic heart disease (P < 0.05), arrhythmias (P < 0.001) and bradycardia (P < 0.01). A higher mortality from heart disease (P < 0.01) was found in men with RBBB compared to the control population. This was not significant when risk factors of heart disease were taken into account by multivariate Cox analysis. There was a relationship (P < 0.05) between hypertension and RBBB in women younger than 60 years. RBBB in women younger than 60 years is often associated with hypertension and in men younger than 60 it is often associated with an underlying cardiovascular disease, hypertension, cardiomegaly and elevated blood glucose

Increasing glucose levels and BMI predict future heart failure Experience from the Reykjavík Study

To access publisher full text version of this article. Please click on the hyperlink in Additional Link fieldBACKGROUND: Heart failure is common in diabetes and ischaemic heart disease is the most likely link. Still, it has been suggested that the relation extends beyond such disease. METHODS: 7060 subjects with two or more visits in the Reykjavík Study were followed-during 30 years from 1967. All underwent oral glucose tolerance tests. Disease status was defined according to the glycaemic level and presence of heart failure. The incidence and predictive factors for these diseases were determined. FINDINGS: Age and sex standardized incidence of heart failure was 5.3/1000/year, of diabetes 4.6/1000/year and abnormal glucose regulation 12.6/1000/year. Body mass index (BMI) and fasting glucose predicted the development of these conditions (p<0.001). Increasing fasting glucose by 1 mmol/l increased the risk for heart failure by 14% (p=0.04) after adjusting for IHD, BMI and other risk factors for CVD. There was a strong association between diabetes and heart failure, OR 3.0 (2.3-4.0), and abnormal glucose regulation and heart failure, OR 1.8 (1.5-2.3). Diabetes and heart failure were, however, not independent predictors of each other. INTERPRETATION: There was an independent relationship between increases in fasting glucose and development of heart failure. BMI was a strong predictor of heart failure. Although fasting glucose and BMI were significant risk factors for glucose disturbances and heart failure the conditions themselves did not independently predict each other

Sural nerve biopsy may predict future nerve dysfunction

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldOBJECTIVE: Sural nerve pathology in peripheral neuropathy shows correlation with clinical findings and neurophysiological tests. The aim was to investigate progression of nerve dysfunction over time in relation to a baseline nerve biopsy. METHODS: Baseline myelinated nerve fiber density (MNFD) was assessed in sural nerve biopsies from 10 men with type 2 diabetes, 10 with impaired and 10 with normal glucose tolerance. Nerve conduction and quantitative perception thresholds were estimated at baseline and follow-up (7-10 years later). RESULTS: Subjects with low MNFD (< or = 4700 fibers/mm(2)) showed decline of peroneal amplitude (P < 0.02) and conduction velocity (P < 0.04), as well as median nerve sensory amplitude (P < 0.05) and motor conduction velocity (P < 0.04) from baseline to follow-up. In linear regression analyses, diabetes influenced decline of nerve conduction. MNFD correlated negatively with body mass index (r = -0.469; P < 0.02). CONCLUSION: Low MNFD may predict progression of neurophysiological dysfunction and links obesity to myelinated nerve fiber loss

Sural nerve biopsy may predict future nerve dysfunction

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldOBJECTIVE: Sural nerve pathology in peripheral neuropathy shows correlation with clinical findings and neurophysiological tests. The aim was to investigate progression of nerve dysfunction over time in relation to a baseline nerve biopsy. METHODS: Baseline myelinated nerve fiber density (MNFD) was assessed in sural nerve biopsies from 10 men with type 2 diabetes, 10 with impaired and 10 with normal glucose tolerance. Nerve conduction and quantitative perception thresholds were estimated at baseline and follow-up (7-10 years later). RESULTS: Subjects with low MNFD (< or = 4700 fibers/mm(2)) showed decline of peroneal amplitude (P < 0.02) and conduction velocity (P < 0.04), as well as median nerve sensory amplitude (P < 0.05) and motor conduction velocity (P < 0.04) from baseline to follow-up. In linear regression analyses, diabetes influenced decline of nerve conduction. MNFD correlated negatively with body mass index (r = -0.469; P < 0.02). CONCLUSION: Low MNFD may predict progression of neurophysiological dysfunction and links obesity to myelinated nerve fiber loss